Literature DB >> 24100981

Semagacestat's fall: where next for AD therapies?

Kaj Blennow, Henrik Zetterberg, Christian Haass, Thomas Finucane.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24100981     DOI: 10.1038/nm.3365

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  16 in total

1.  Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Authors:  J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

2.  Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons.

Authors:  Peer-Hendrik Kuhn; Katarzyna Koroniak; Sebastian Hogl; Alessio Colombo; Ulrike Zeitschel; Michael Willem; Christiane Volbracht; Ute Schepers; Axel Imhof; Albrecht Hoffmeister; Christian Haass; Steffen Roßner; Stefan Bräse; Stefan F Lichtenthaler
Journal:  EMBO J       Date:  2012-06-22       Impact factor: 11.598

3.  Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.

Authors:  Adam S Fleisher; Rema Raman; Eric R Siemers; Lida Becerra; Christopher M Clark; Robert A Dean; Martin R Farlow; James E Galvin; Elaine R Peskind; Joseph F Quinn; Abdullah Sherzai; B Brooke Sowell; Paul S Aisen; Leon J Thal
Journal:  Arch Neurol       Date:  2008-08

4.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

Authors:  Rachelle S Doody; Rema Raman; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Feng He; Xiaoying Sun; Ronald G Thomas; Paul S Aisen; Eric Siemers; Gopalan Sethuraman; Richard Mohs
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

5.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

6.  Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis.

Authors:  X Xia; S Qian; S Soriano; Y Wu; A M Fletcher; X J Wang; E H Koo; X Wu; H Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

Review 7.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Harald Hampel; Michael Weiner; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

8.  A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease.

Authors:  Erik Portelius; Robert A Dean; Mikael K Gustavsson; Ulf Andreasson; Henrik Zetterberg; Eric Siemers; Kaj Blennow
Journal:  Alzheimers Res Ther       Date:  2010-03-29       Impact factor: 6.982

9.  Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.

Authors:  Gwendolyn T Wong; Denise Manfra; Frederique M Poulet; Qi Zhang; Hubert Josien; Thomas Bara; Laura Engstrom; Maria Pinzon-Ortiz; Jay S Fine; Hu-Jung J Lee; Lili Zhang; Guy A Higgins; Eric M Parker
Journal:  J Biol Chem       Date:  2004-01-06       Impact factor: 5.157

10.  Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene.

Authors:  D Levitan; I Greenwald
Journal:  Nature       Date:  1995-09-28       Impact factor: 49.962

View more
  7 in total

Review 1.  Advances in recent patent and clinical trial drug development for Alzheimer's disease.

Authors:  Haibin Liu; Lirong Wang; Weiwei Su; Xiang-Qun Xie
Journal:  Pharm Pat Anal       Date:  2014-07

2.  A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease.

Authors:  Anna E Tschiffely; Rosemary A Schuh; Katalin Prokai-Tatrai; Laszlo Prokai; Mary Ann Ottinger
Journal:  Horm Behav       Date:  2016-05-19       Impact factor: 3.587

3.  Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.

Authors:  Sebastian Palmqvist; Henrik Zetterberg; Niklas Mattsson; Per Johansson; Lennart Minthon; Kaj Blennow; Mattias Olsson; Oskar Hansson
Journal:  Neurology       Date:  2015-09-09       Impact factor: 9.910

Review 4.  Important advances in Alzheimer's disease from the use of induced pluripotent stem cells.

Authors:  Fernanda Majolo; Daniel Rodrigo Marinowic; Denise Cantarelli Machado; Jaderson Costa Da Costa
Journal:  J Biomed Sci       Date:  2019-02-06       Impact factor: 8.410

5.  Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission.

Authors:  Tugce Munise Satir; Lotta Agholme; Anna Karlsson; Mattias Karlsson; Paul Karila; Sebastian Illes; Petra Bergström; Henrik Zetterberg
Journal:  Alzheimers Res Ther       Date:  2020-05-26       Impact factor: 6.982

6.  η-Secretase processing of APP inhibits neuronal activity in the hippocampus.

Authors:  Michael Willem; Sabina Tahirovic; Marc Aurel Busche; Saak V Ovsepian; Magda Chafai; Scherazad Kootar; Daniel Hornburg; Lewis D B Evans; Steven Moore; Anna Daria; Heike Hampel; Veronika Müller; Camilla Giudici; Brigitte Nuscher; Andrea Wenninger-Weinzierl; Elisabeth Kremmer; Michael T Heneka; Dietmar R Thal; Vilmantas Giedraitis; Lars Lannfelt; Ulrike Müller; Frederick J Livesey; Felix Meissner; Jochen Herms; Arthur Konnerth; Hélène Marie; Christian Haass
Journal:  Nature       Date:  2015-08-31       Impact factor: 49.962

7.  Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment.

Authors:  M Brendel; A Jaworska; J Herms; J Trambauer; C Rötzer; F-J Gildehaus; J Carlsen; P Cumming; J Bylund; T Luebbers; P Bartenstein; H Steiner; C Haass; K Baumann; A Rominger
Journal:  Mol Psychiatry       Date:  2015-06-09       Impact factor: 15.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.